The global Interstitial Cystitis drugs market size is USD xx billion in 2019 and projected to reach USD xx billion by 2028, exhibiting a CAGR of xx% during the forecast period.
Interstitial cystitis is termed as painful bladder syndrome is defined as a debleating condition where there is a pain in the lower abdomen and problems in passing urine. It can occur in any age group, but it is more common in younger age group. Global interstitial cystitis market is expected to gain market growth in the forecast period of 2019 to 2028. Emerging markets and huge investment in research and development are the factors responsible for the growth of this market. The growth of interstitial cystitis market enhanced by the growing cases of interstitial cystitis as well as bladder trauma or overstretching and rise in research and development activities, advances in the technology and adoption of sedentary lifestyle are some of the impacting factors for the demand of interstitial cystitis drugs. However, the IC drugs market is currently weak due to limitations regarding the efficacy and compliance of available products. Other factors include limited approved treatment options, lack of awareness, and need for disease modifying therapies
The high prevalence of interstitial cystitis is driving the global Interstitial Cystitis Drugs Market. The advent of gene therapy is positively impacting the global market. Most of the approved and off-label drugs for interstitial cystitis are small molecules, which cannot completely cure the disease, have side effects on the patients, and are expensive. Owing to the disadvantages of available drugs for interstitial cystitis, companies are developing innovative treatment options such as, regenerative therapy and gene therapy that have fewer side effects. The development of such therapies will drive demand. Thus, the high prevalence of interstitial cystitis coupled with the advent of gene therapy will drive the Interstitial Cystitis Drugs Market size growth during the forecast period